Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of AMG 706 in advanced GIST after imatinib failure
2004-002165-20Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of motesanib in gastrointestinal stromal tumor (GIST), sponsored by Amgen. Primary endpoint: Objective response rate. Started Feb 2005; status: completed.
02
Drugs
motesanib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2004-002165-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002165-20.